DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Australia Market Report for Uterine Fibroid Embolization Devices 2017 - MedCore" report to their offering.
The UFE market has decreased in growth in part because of a reduction in active marketing. Moreover, UFE must compete with a wide array of procedures available to treat heavy bleeding due to uterine fibroids. These other treatments and procedures include hysterectomy, pharmacological alternatives, global endometrial ablation, endometrial resection and other minimally invasive surgical procedures. The complete market is comprised of the microsphere and PVA particle sub-segments respectively. Despiute the overall decrease in the market, the microspheres segment is increasing significantly.
The volume of microspheres required per procedure is much higher than the volume of PVA particles required per procedure; 3.5 microspheres are used for every 2 PVA particles required per procedure. The shift towards microspheres has diminished the severity of the drop in unit sales being caused by the declining procedure numbers. Physicians may prefer the use of microspheres over PVA particles due to peer-reviewed journals that outline how microspheres result in reduced blood loss and higher efficacy in the reduction of fibroids compared to the alternative. PVA particles have been popular in the past due to their affordability and they were previously considered the standard of care.
Key Topics Covered:
1. Research Methodology
2. Disease Overview
3. Product Assessment
4. Uterine Fibroid Embolization Device Market
For more information about this report visit http://www.researchandmarkets.com/research/jz2q2q/australia_market